Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies

OBJECTIVES: The complement component 5 (C5) inhibitor ravulizumab demonstrated non‐inferiority to eculizumab following 26 weeks of treatment in complement inhibitor‐naïve and complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively)....

Descripción completa

Detalles Bibliográficos
Autores principales: Kulasekararaj, Austin G., Griffin, Morag, Langemeijer, Saskia, Usuki, Kensuke, Kulagin, Alexander, Ogawa, Masayo, Yu, Ji, Mujeebuddin, Arshad, Nishimura, Jun‐ichi, Lee, Jong Wook, Peffault de Latour, Régis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546219/
https://www.ncbi.nlm.nih.gov/pubmed/35502600
http://dx.doi.org/10.1111/ejh.13783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546219/
https://www.ncbi.nlm.nih.gov/pubmed/35502600
http://dx.doi.org/10.1111/ejh.13783

Ejemplares similares